{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T13:34:36Z","timestamp":1790429676323,"version":"4.1.0"},"reference-count":204,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Econ Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Health promotion and disease prevention are receiving increasing attention in Germany because of their potential to improve population health and reduce healthcare costs. Health-economic evaluations (HEEs) are essential for informing evidence-based decision-making in this field. However, HEEs of preventive interventions often face methodological challenges. This scoping review examines the current state and characteristics of HEEs conducted in the context of health promotion and disease prevention in Germany.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A scoping review was conducted to map the landscape of HEE of health promotion and disease prevention interventions in Germany, following a priori\u2013registered protocol. Three bibliographic databases (MEDLINE, EMBASE and Web of Science) were searched from their inception to March 2025. The screening of titles, abstracts, and full texts was performed in a blinded, double-reviewer, and stepwise manner using predefined inclusion criteria: (i) focus on the German population, (ii) application of an HEE as the primary research method, and (iii) evaluation of a health-promoting or disease-preventing intervention. Studies focusing on tertiary prevention were excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 4,632 records identified, 162 eligible original studies met the inclusion criteria. The volume of published HEEs has increased over time. Most studies (53.7%) assessed primary preventive interventions. Cost-effectiveness analysis was the most frequently applied HEE analysis type. Incremental cost-effectiveness ratios (ICERs) are commonly reported as incremental costs per quality-adjusted life year (QALY) gained (42.4% of all ICERs). In 85.2% of the studies, the intervention was judged to be cost-effective. A model-based approach was used in 75.9% of the studies, and 81.3% of these studies relied partly on non-German data sources. More than half of all studies (56.1%) reported limitations due to a lack of German-specific data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>HEEs related to health promotion and disease prevention interventions in Germany exhibit substantial methodological heterogeneity. Frequent reliance on non-German data and the large proportion of interventions deemed cost-effective may reflect contextual data gaps and potential publication bias. These issues complicate the interpretation of economic evidence and pose challenges for decision-makers seeking to prioritize preventive strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>https:\/\/osf.io\/h6749\/overview<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13561-026-00859-0","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:04:23Z","timestamp":1790312663000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Health economic evaluation of health promotion and disease prevention in Germany: a scoping review"],"prefix":"10.1186","volume":"16","author":[{"given":"Eva Juliane","family":"Beer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Kirschneck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Coenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2817-9359","authenticated-orcid":false,"given":"Rosa Maria Sija","family":"Visscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"859_CR1","unstructured":"World Health Organization. Ottawa Charter for Health Promotion. 1986. Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/349652\/WHO-EURO-1986-4044-4380361677-eng.pdf. Accessed 30 Jun 2025."},{"key":"859_CR2","unstructured":"World Health Organization. Glossary of terms used in the health for all series, No. 1\u20138. Geneva: World Health Organization. 1984. Available from: https:\/\/iris.who.int\/handle\/10665\/39565. Accessed 30 Jun 2025."},{"key":"859_CR3","volume-title":"Methods for the eco nomic evaluation of health care programmes","author":"MF Drummond","year":"2015","unstructured":"Drummond MF, Sculpher M, Claxton K, Stoddart GL, Torrance GW. Methods for the eco nomic evaluation of health care programmes. Oxford: Oxford University Press. 2015."},{"key":"859_CR4","unstructured":"McDaid D. Using economic evidence to help make the case for investing in health pro motion and disease prevention. Policy Brief. 2018. Available from: https:\/\/iris.who.int\/handle\/10665\/331981. Accessed 30 Jun 2025."},{"key":"859_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/978-3-642-21700-5_3","volume-title":"Gesundheits\u00f6konomische Evaluationen","author":"W Greiner","year":"2012","unstructured":"Greiner W, Damm O. Die Berechnung von Kosten und Nutzen. In: Sch\u00f6ffski O, von der Graf J-M, editors. Gesundheits\u00f6konomische Evaluationen. Berlin, Heidelberg. Springer Berlin Heidelberg. 2012; pp. 23\u201342. https:\/\/doi.org\/10.1007\/978-3-642-21700-5_3."},{"key":"859_CR6","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/978-3-658-31434","volume-title":"Forschungsmethoden in der Gesundheitsf\u00f6rderung und Pr\u00e4vention","author":"L Hasemann","year":"2021","unstructured":"Hasemann L, D\u00fcvel J, Gruhn S, Greiner W. Gesundheits\u00f6konomische evaluation in der Gesundheitsf\u00f6rderung und Pr\u00e4vention. In: Niederberger M, Finne E, editors. Forschungsmethoden in der Gesundheitsf\u00f6rderung und Pr\u00e4vention. Wiesbaden: Springer Fachmedien Wiesbaden. 2021; pp. 237\u201367. https:\/\/doi.org\/10.1007\/978-3-658-31434."},{"key":"859_CR7","unstructured":"Statistisches Bundesamt. Demografischer Wandel. 2024. Available from: https:\/\/www.destatis.de\/DE\/Themen\/Querschnitt\/Demografischer-Wandel\/_inhalt.html. Accessed 30 Jun 2025."},{"key":"859_CR8","unstructured":"Robert Koch Institute. Demographic change. 2024. Available from: https:\/\/www.rki.de\/EN\/Topics\/Non communicable-diseases\/Health-in-the-course-of-life\/Demographic-change\/demographic change.html. Accessed 30 Jun 2025."},{"key":"859_CR9","unstructured":"Bundesministerium f\u00fcr Gesundheit. Finanzentwicklung der GKV im 1. bis 3. Quartal 2024. 2024. Available from: https:\/\/www.bundesgesundheitsministerium.de\/presse\/pressemitteilungen\/fi nanzentwicklung-der-gkv-im-1-bis-3-quartal-2024-pm-06-12-2024.html. Accessed 30 Jun 2025."},{"key":"859_CR10","doi-asserted-by":"publisher","unstructured":"Sch\u00f6ffski O. Grundformen gesundheits\u00f6konomischer Evaluationen. In: Sch\u00f6ffski O, Graf von der Schulenburg J-M, editors. Gesundheits\u00f6konomische Evaluationen. Berlin, Heidelberg: Springer Berlin Heidelberg. 2012; pp. 43\u201370. https:\/\/doi.org\/10.1007\/978-3-642","DOI":"10.1007\/978-3-642"},{"key":"859_CR11","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1146\/annurev.publhealth.21.1","volume":"21","author":"P Neumann","year":"2000","unstructured":"Neumann P, Goldie S, Weinstein M. Preference-based measures in economic evaluation in health care. Annu Rev Public Health. 2000;21:587\u2013611. https:\/\/doi.org\/10.1146\/annurev.publhealth.21.1.","journal-title":"Annu Rev Public Health"},{"key":"859_CR12","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/978-3-642-21700-5_8","volume-title":"Gesundheits\u00f6konomische Evaluationen","author":"S Eisenreich","year":"2012","unstructured":"Eisenreich S, Bierbaum M, Sohn S, Sch\u00f6ffski O. Budget Impact Analysen. In: Sch\u00f6ffski O, von der Graf J-M, editors. Gesundheits\u00f6konomische Evaluationen. Berlin, Heidelberg: Springer Berlin Heidelberg. 2012; pp. 181\u201393. https:\/\/doi.org\/10.1007\/978-3-642-21700-5_8."},{"key":"859_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12916-021-02204-0","volume":"20","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Med. 2022;20:23. https:\/\/doi.org\/10.1186\/s12916-021-02204-0.","journal-title":"BMC Med"},{"key":"859_CR14","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.jval.2012.06.012","volume":"15","author":"JJ Caro","year":"2012","unstructured":"Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices\u2014overview: a report of the ISPOR-SMDM modeling good research practices task force-1. Value health: J Int Soc Pharmacoeconomics Outcomes Res. 2012;15:796\u2013803. https:\/\/doi.org\/10.1016\/j.jval.2012.06.012.","journal-title":"Value health: J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"859_CR15","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.jval.2024.07.027","volume":"27","author":"M Soares","year":"2024","unstructured":"Soares M, Colson A, Bojke L, Ghabri S, Garay OU, Felli JK, et al. Recommendations on the use of structured expert elicitation protocols for healthcare decision making: a good practices report of an ISPOR task force. Value Health. 2024;27:1469\u201378. https:\/\/doi.org\/10.1016\/j.jval.2024.07.027.","journal-title":"VALUE HEALTH"},{"key":"859_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jval.2024.09.001","volume":"28","author":"S Botwright","year":"2025","unstructured":"Botwright S, Sittimart M, Chavarina KK, Bayani DB, Merlin T, Surgey G, et al. Good Practices for health technology assessment guideline development: a report of the health technology assessment international, HTAsiaLink, and ISPOR Special Task Force. Value Health. 2025;28:1\u201315. https:\/\/doi.org\/10.1016\/j.jval.2024.09.001.","journal-title":"VALUE HEALTH"},{"key":"859_CR17","unstructured":"National Institute for Health and Clinical Excellence. NICE health technology evaluations: the manual. 2025. Available from: https:\/\/www.nice.org.uk\/process\/pmg36. Accessed 30 Jun 2025."},{"key":"859_CR18","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit Im Gesundheitswesen. Allgemeine Methoden: Version 7.0. 2023. Available from: https:\/\/www.iqwig.de\/methoden\/allgemeine-methoden_version-7 0.pdf. Accessed 30 Jun 2025."},{"key":"859_CR19","unstructured":"Robert Koch Institute. Modelling methods for predicting epidemiological and health eco nomic effects of vaccinations - Guidance for analyses to be presented to the German Standing Commitee on Vaccination (STIKO). 2024. Available from: https:\/\/www.rki.de\/EN\/Topics\/Infectious-diseases\/Immunisation\/STIKO\/STIKO-methodology\/Guidance_for_analyses.pdf?__blob=publicationFile&v=1. Accessed 30 Jun 2025."},{"key":"859_CR20","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1055\/s-2007-963505","volume":"12","author":"J-M von der Graf","year":"2007","unstructured":"von der Graf J-M, Greiner W, Jost F, Klusen N, Kubin M, Leidl R, et al. Deutsche Empfehlungen zur gesundheits\u00f6konomischen Evaluation - dritte und aktualisierte Fassung des Hannoveraner Konsens. [German recommendations on health economic evaluation - Third and updated version of the Hanover Consensus]. Gesundheits\u00f6konomie und Qualit\u00e4tsmanagement. 2007;12:285\u201390.","journal-title":"Gesundheits\u00f6konomie und Qualit\u00e4tsmanagement"},{"key":"859_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-021-12174-w","author":"Y Seleznova","year":"2021","unstructured":"Seleznova Y, Alayli A, Stock S, M\u00fcller D. Methodological issues in economic evaluations of disease prevention and health promotion: an overview of systematic and scoping reviews. BMC Public Health. 2021. https:\/\/doi.org\/10.1186\/s12889-021-12174-w.","journal-title":"BMC Public Health"},{"key":"859_CR22","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.11124\/JBIES-20-00167","volume":"18","author":"MDJ Peters","year":"2020","unstructured":"Peters MDJ, Marnie C, Tricco AC, Pollock D, Munn Z, Alexander L, et al. Updated methodological guidance for the conduct of scoping reviews. JBI Evid Synthesis. 2020;18:2119\u201326. https:\/\/doi.org\/10.11124\/JBIES-20-00167.","journal-title":"JBI Evid Synthesis"},{"key":"859_CR23","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, O\u2019Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018;169:467\u201373. https:\/\/doi.org\/10.7326\/M18-0850.","journal-title":"Ann Intern Med"},{"key":"859_CR24","unstructured":"Beer EJ, Visscher RMS, Coenen M, Kirschneck M, Bernhard L, Hennig A. Status Quo of health-economic evaluations in health promotion and prevention in Germany: A scoping review: Study protocol. 2025. https:\/\/osf.io\/h6749. Accessed 30 Jun 2025."},{"key":"859_CR25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1024\/86350-000","volume-title":"Referenzwerk Pr\u00e4vention und Gesundheitsf\u00f6rderung","author":"A Leppin","year":"2024","unstructured":"Leppin A, Blunck L. 3 Konzepte und Strategien der Pr\u00e4vention. In: Hurrelmann Klaus R, Matthias S, Stephanie, editors. Referenzwerk Pr\u00e4vention und Gesundheitsf\u00f6rderung. Bern: Hogrefe; 2024. pp. 47\u201354. https:\/\/doi.org\/10.1024\/86350-000."},{"key":"859_CR26","doi-asserted-by":"publisher","unstructured":"Aromataris E, Lockwood C, Porritt K, Pilla B, Jordan Z. JBI Manual for Evidence Synthesis. JBI; 2024. https:\/\/doi.org\/10.46658\/JBIMES-24-01.","DOI":"10.46658\/JBIMES-24-01"},{"key":"859_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/978-3642-21700-5_1","volume-title":"Gesundheits\u00f6konomische Evaluationen","year":"2012","unstructured":"Sch\u00f6ffski O, von der Graf J-M, editors. Gesundheits\u00f6konomische Evaluationen. Berlin, Heidelberg: Springer Berlin Heidelberg; 2012. https:\/\/doi.org\/10.1007\/978-3642-21700-5_1."},{"key":"859_CR28","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2165\/00019053","volume":"19","author":"B Liljas","year":"2001","unstructured":"Liljas B, Lindgren B. On individual preferences and aggregation in economic evaluation in healthcare. PharmacoEconomics. 2001;19:323\u201335. https:\/\/doi.org\/10.2165\/00019053.","journal-title":"PharmacoEconomics"},{"key":"859_CR29","doi-asserted-by":"publisher","first-page":"e1230","DOI":"10.1002\/cl2.1230","volume":"18","author":"NR Haddaway","year":"2022","unstructured":"Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis. Campbell Syst Reviews. 2022;18:e1230. https:\/\/doi.org\/10.1002\/cl2.1230.","journal-title":"Campbell Syst Reviews"},{"key":"859_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004311","author":"KM Emmert-Fees","year":"2023","unstructured":"Emmert-Fees KM, Amies-Cull B, Wawro N, Linseisen J, Staudigel M, Peters A, et al. Projected health and economic impacts of sugar-sweetened beverage taxation in Germany: A cross-validation modelling study. PLoS Med. 2023. https:\/\/doi.org\/10.1371\/journal.pmed.1004311.","journal-title":"PLoS Med"},{"key":"859_CR31","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.puhe.2007.05.007","volume":"122","author":"D Hoeflmayr","year":"2008","unstructured":"Hoeflmayr D, Hanewinkel R. Do school-based tobacco prevention programmes pay off? The cost-effectiveness of the \u2018Smoke-free Class Competition\u2019. Public Health. 2008;122:34\u201341. https:\/\/doi.org\/10.1016\/j.puhe.2007.05.007.","journal-title":"Public Health"},{"key":"859_CR32","doi-asserted-by":"publisher","first-page":"e0172332","DOI":"10.1371\/journal.pone.0172332","volume":"12","author":"D Kesztyus","year":"2017","unstructured":"Kesztyus D, Lauer R, Kesztyus T, Kilian R, Steinacker JM, Group. Join the Healthy Boat Study. Costs and effects of a state-wide health promotion program in primary schools in Germany - the Baden-Wurttemberg Study: A cluster-randomized, controlled trial. PLoS ONE. 2017;12:e0172332. https:\/\/doi.org\/10.1371\/journal.pone.0172332.","journal-title":"PLoS ONE"},{"key":"859_CR33","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10198-011-0358-3","volume":"14","author":"D Kesztyus","year":"2013","unstructured":"Kesztyus D, Schreiber A, Wirt T, Wiedom M, Dreyhaupt J, Brandstetter S, et al. Economic evaluation of URMEL-ICE, a school-based overweight prevention programme comprising metabolism, exercise and lifestyle intervention in children. Eur J health economics: HEPAC : health Econ Prev care. 2013;14:185\u201395. https:\/\/doi.org\/10.1007\/s10198-011-0358-3.","journal-title":"Eur J health economics: HEPAC : health Econ Prev care"},{"key":"859_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13561-02000266-z","author":"R Lauer","year":"2020","unstructured":"Lauer R, Traub M, Hansen S, Kilian R, Steinacker JM, Keszty\u00fcs D. Longitudinal changes and determinants of parental willingness to pay for the prevention of childhood overweight and obesity. Health Econ Rev. 2020. https:\/\/doi.org\/10.1186\/s13561-02000266-z.","journal-title":"Health Econ Rev"},{"key":"859_CR35","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1093\/ntr\/ntz124","volume":"22","author":"T Le\u00e3o","year":"2020","unstructured":"Le\u00e3o T, Perelman J, Clancy L, Mlinari\u0107 M, Kinnunen JM, Nuyts PAW, et al. Economic Evaluation of Five Tobacco Control Policies Across Seven European Countries. Nicotine Tob Res. 2020;22:1202\u20139. https:\/\/doi.org\/10.1093\/ntr\/ntz124.","journal-title":"Nicotine Tob Res"},{"key":"859_CR36","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.puhe.2020.06.012","volume":"186","author":"LM Lier","year":"2020","unstructured":"Lier LM, Breuer C, Ferrari N, Friesen D, Maisonave F, Schmidt N, Graf C. Cost-effectiveness of a family-based multicomponent outpatient intervention program for children with obesity in Germany. Public Health. 2020;186:185\u201392. https:\/\/doi.org\/10.1016\/j.puhe.2020.06.012.","journal-title":"Public Health"},{"key":"859_CR37","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1186\/s12889-019-7585-4","volume":"19","author":"G Muller","year":"2019","unstructured":"Muller G, Pfinder M, Schmahl C, Bohus M, Lyssenko L. Cost-effectiveness of a mindfulness-based mental health promotion program: economic evaluation of a nonrandomized controlled trial with propensity score matching. BMC Public Health. 2019;19:1309. https:\/\/doi.org\/10.1186\/s12889-019-7585-4.","journal-title":"BMC Public Health"},{"key":"859_CR38","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1001\/archinternmed.2008.556","volume":"169","author":"HJ Salize","year":"2009","unstructured":"Salize HJ, Merkel S, Reinhard I, Twardella D, Mann K, Brenner H. Cost-effective primary care-based strategies to improve smoking cessation: more value for money. Arch Intern Med. 2009;169:230\u20136. https:\/\/doi.org\/10.1001\/archinternmed.2008.556.","journal-title":"Arch Intern Med"},{"key":"859_CR39","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00392-011-0385-1","volume":"101","author":"JD Sargent","year":"2012","unstructured":"Sargent JD, Demidenko E, Malenka DJ, Li Z, Gohlke H, Hanewinkel R. Smoking restrictions and hospitalization for acute coronary events in Germany. Clin Res cardiology: official J German Cardiac Soc. 2012;101:227\u201335. https:\/\/doi.org\/10.1007\/s00392-011-0385-1.","journal-title":"Clin Res cardiology: official J German Cardiac Soc"},{"key":"859_CR40","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/j.1524-4733.2006.00157.x","volume":"10","author":"S Aballea","year":"2007","unstructured":"Aballea S, Chancellor J, Martin M, Wutzler P, Carrat F, Gasparini R, et al. The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: An international model. VALUE HEALTH. 2007;10:98\u2013116. https:\/\/doi.org\/10.1111\/j.1524-4733.2006.00157.x.","journal-title":"VALUE HEALTH"},{"key":"859_CR41","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1016\/j.vaccine.2014.01.061","volume":"32","author":"P Aidelsburger","year":"2014","unstructured":"Aidelsburger P, Grabein K, Bohm K, Dietl M, Wasem J, Koch J, et al. Cost-effectiveness of childhood rotavirus vaccination in Germany. Vaccine. 2014;32:1964\u201374. https:\/\/doi.org\/10.1016\/j.vaccine.2014.01.061.","journal-title":"Vaccine"},{"key":"859_CR42","doi-asserted-by":"publisher","first-page":"EP1","DOI":"10.1080\/14760584.2024.2436183","volume":"24","author":"A Averin","year":"2025","unstructured":"Averin A, Huebbe B, Atwood M, Bayer LJ, Lade C, von Eiff C, Sato R. Cost-effectiveness of bivalent respiratory syncytial virus prefusion F vaccine for prevention of respiratory syncytial virus among older adults in Germany. Expert Rev Vaccines. 2025;24:EP1\u201310. https:\/\/doi.org\/10.1080\/14760584.2024.2436183.","journal-title":"Expert Rev Vaccines"},{"key":"859_CR43","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/s0264-410x(02)00431-0","volume":"21","author":"K Banz","year":"2003","unstructured":"Banz K, Wagenpfeil S, Neiss A, Goertz A, Staginnus U, Vollmar J, Wutzler P. The cost-effectiveness of routine childhood varicella vaccination in Germany. Vaccine. 2003;21:1256\u201367. https:\/\/doi.org\/10.1016\/s0264-410x(02)00431-0.","journal-title":"Vaccine"},{"key":"859_CR44","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1016\/j.jval.2022.04.1736","volume":"25","author":"CC Bartenschlager","year":"2022","unstructured":"Bartenschlager CC, Temizel S, Ebigbo A, Gruenherz V, Gastmeier P, Messmann H, et al. A simulation-based cost-effectiveness analysis of severe acute respiratory syndrome coronavirus 2 infection prevention strategies for visitors of healthcare institutions. Value health: J Int Soc Pharmacoeconomics Outcomes Res. 2022;25:1846\u201352. https:\/\/doi.org\/10.1016\/j.jval.2022.04.1736.","journal-title":"Value health: J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"859_CR45","doi-asserted-by":"publisher","first-page":"S335","DOI":"10.1093\/infdis\/174.supplement_3.s335","volume":"174","author":"P Beutels","year":"1996","unstructured":"Beutels P, Clara R, Tormans G, van Doorslaer E, van Damme P. Costs and benefits of routine varicella vaccination in German children. J Infect Dis. 1996;174:S335\u201341. https:\/\/doi.org\/10.1093\/infdis\/174.supplement_3.s335.","journal-title":"J Infect Dis"},{"key":"859_CR46","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12913-015-0817-0","volume":"15","author":"C Brettschneider","year":"2015","unstructured":"Brettschneider C, Luck T, Fleischer S, Roling G, Beutner K, Luppa M, et al. Cost-utility analysis of a preventive home visit program for older adults in Germany. BMC Health Serv Res. 2015;15:141. https:\/\/doi.org\/10.1186\/s12913-015-0817-0.","journal-title":"BMC Health Serv Res"},{"key":"859_CR47","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1080\/13696998.2021.1908000","volume":"24","author":"R Cai","year":"2021","unstructured":"Cai R, Gerlier L, Eichner M, Schwehm M, Rajaram S, Mould-Quevedo J, Lamotte M. Cost-effectiveness of the cell-based quadrivalent versus the standard egg-based quadrivalent influenza vaccine in Germany. J Med Econ. 2021;24:490\u2013501. https:\/\/doi.org\/10.1080\/13696998.2021.1908000.","journal-title":"J Med Econ"},{"key":"859_CR48","doi-asserted-by":"publisher","first-page":"EP3412","DOI":"10.1016\/j.vaccine.2016.04.004","volume":"34","author":"H Christensen","year":"2016","unstructured":"Christensen H, Irving T, Koch J, Trotter CL, Ultsch B, Weidemann F, et al. Epidemiological impact and cost-effectiveness of universal vaccination with Bexsero to reduce meningococcal group B disease in Germany. Vaccine. 2016;34:EP3412\u20133419. https:\/\/doi.org\/10.1016\/j.vaccine.2016.04.004.","journal-title":"Vaccine"},{"key":"859_CR49","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1017\/S0266462310000280","volume":"26","author":"A Cicchetti","year":"2010","unstructured":"Cicchetti A, Ruggeri M, Gitto L, Mennini FS. Extending influenza vaccination to individuals aged 50\u201364: A budget impact analysis. Int J Technol Assess Health Care. 2010;26:288\u201393. https:\/\/doi.org\/10.1017\/S0266462310000280.","journal-title":"Int J Technol Assess Health Care"},{"key":"859_CR50","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2165\/00019053-20032108000005","volume":"21","author":"C Claes","year":"2003","unstructured":"Claes C, von der Graf J-M. Cost effectiveness of pneumococcal vaccination for infants and children with the conjugate vaccine PnC-7 in Germany. PharmacoEconomics. 2003;21:587. https:\/\/doi.org\/10.2165\/00019053-20032108000005. EP\u2009\u2013\u2009600.","journal-title":"PharmacoEconomics"},{"key":"859_CR51","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s10198008-0098-1","volume":"10","author":"C Claes","year":"2009","unstructured":"Claes C, Reinert RR, Graf von der Schulenburg J-M. Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects. Eur J Health Econ. 2009;10:25\u201338. https:\/\/doi.org\/10.1007\/s10198008-0098-1.","journal-title":"Eur J Health Econ"},{"key":"859_CR52","doi-asserted-by":"publisher","unstructured":"Coudeville L, Brunot A, Szucs TD, Dervaux B. The economic value of childhood varicella vaccination in France and Germany. Value Health. 2005;8. https:\/\/doi.org\/10.1111\/j.1524-4733.2005.04005.x. :209 EP\u2009\u2013\u2009222.","DOI":"10.1111\/j.1524-4733.2005.04005.x"},{"key":"859_CR53","doi-asserted-by":"publisher","first-page":"5296","DOI":"10.1080\/21645515.2021.2002085","volume":"17","author":"D Curran","year":"2021","unstructured":"Curran D, van Oorschot D, Matthews S, Hain J, Salem AE, Schwarz M. Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany. Hum vaccines immunotherapeutics. 2021;17:5296\u2013303. https:\/\/doi.org\/10.1080\/21645515.2021.2002085.","journal-title":"Hum vaccines immunotherapeutics"},{"key":"859_CR54","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s10198-014-0586-4","volume":"16","author":"O Damm","year":"2015","unstructured":"Damm O, Eichner M, Rose MA, Knuf M, Wutzler P, Liese JG, et al. Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany. Eur J health economics: HEPAC: health Econ Prev care. 2015;16:471\u201388. https:\/\/doi.org\/10.1007\/s10198-014-0586-4.","journal-title":"Eur J health economics: HEPAC: health Econ Prev care"},{"key":"859_CR55","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12962-017-0080-9","volume":"15","author":"O Damm","year":"2017","unstructured":"Damm O, Horn J, Mikolajczyk RT, Kretzschmar MEE, Kaufmann AM, Deler\u00e9 Y, et al. Cost-effectiveness of human papillomavirus vaccination in Germany. Cost Eff Resour Alloc. 2017;15:18. https:\/\/doi.org\/10.1186\/s12962-017-0080-9.","journal-title":"Cost Eff Resour Alloc"},{"key":"859_CR56","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s12877-024-04802-y","volume":"24","author":"J Dams","year":"2024","unstructured":"Dams J, Gottschalk S, Schwenk M, Nerz C, Becker C, Klenk J, et al. Budget impact analysis of a Lifestyle-integrated Functional Exercise (LiFE) program for older people in Germany: a Markov model based on data from the LiFE-is-LiFE trial. BMC Geriatr. 2024;24:186. https:\/\/doi.org\/10.1186\/s12877-024-04802-y.","journal-title":"BMC Geriatr"},{"key":"859_CR57","doi-asserted-by":"publisher","first-page":"EP96","DOI":"10.1007\/s101980100069","volume":"2","author":"R Diel","year":"2001","unstructured":"Diel R, Rappenhoner B, Schneider S. Cost-effectiveness of hepatitis A immunization of children and adolescents in Germany. HEPAC Health Econ Prev Care. 2001;2:EP96\u2013103.","journal-title":"HEPAC Health Econ Prev Care"},{"key":"859_CR58","doi-asserted-by":"publisher","first-page":"14318","DOI":"10.3390\/ijerph192114318","volume":"19","author":"S Ellmann","year":"2022","unstructured":"Ellmann S, Maryschok M, Schoffski O, Emmert M. The German COVID-19 Digital Contact Tracing App: A Socioeconomic Evaluation. Int J Environ Res Public Health. 2022;19:14318. https:\/\/doi.org\/10.3390\/ijerph192114318.","journal-title":"Int J Environ Res Public Health"},{"key":"859_CR59","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s10096-007-0327-z","volume":"26","author":"SMAA Evers","year":"2007","unstructured":"Evers SMAA, Ament AJHA, Colombo GL, Konradsen HB, Reinert RR, Sauerland D, et al. Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries. Eur J Clin Microbiol Infect Dis. 2007;26:531\u201340. https:\/\/doi.org\/10.1007\/s10096-007-0327-z.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"859_CR60","doi-asserted-by":"publisher","first-page":"7797","DOI":"10.1016\/j.vaccine.2010.09.037","volume":"28","author":"JM Fischinger","year":"2010","unstructured":"Fischinger JM, Stephan B, Wasserscheid K, Eichler H, Gartner BC. A cost-benefit analysis of blood donor vaccination as an alternative to additional DNA testing for reducing transfusion transmission of hepatitis B virus. Vaccine. 2010;28:7797\u2013802. https:\/\/doi.org\/10.1016\/j.vaccine.2010.09.037.","journal-title":"Vaccine"},{"key":"859_CR61","doi-asserted-by":"publisher","first-page":"e48481","DOI":"10.2196\/48481","volume":"26","author":"J Freund","year":"2024","unstructured":"Freund J, Smit F, Lehr D, Zarski A-C, Berking M, Riper H, et al. A Universal Digital Stress Management Intervention for Employees: Randomized Controlled Trial with Health-Economic Evaluation. J Med Internet Res. 2024;26:e48481. https:\/\/doi.org\/10.2196\/48481.","journal-title":"J Med Internet Res"},{"key":"859_CR62","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/ijo.2012.139","volume":"37","author":"NR Fuller","year":"2013","unstructured":"Fuller NR, Colagiuri S, Schofield D, Olson AD, Shrestha R, Holzapfel C, et al. A within trial cost-effectiveness analysis of primary care referral to a commercial provider for weight loss treatment, relative to standard care\u2014an international randomised controlled trial. Int J Obes (Lond). 2013;37:828\u201334. https:\/\/doi.org\/10.1038\/ijo.2012.139.","journal-title":"Int J Obes (Lond)"},{"key":"859_CR63","doi-asserted-by":"publisher","first-page":"EP51","DOI":"10.1177\/09514848221080687","volume":"36","author":"A Gandjour","year":"2023","unstructured":"Gandjour A. Cost-effectiveness of future lockdown policies against the COVID-19 pandemic. Health Serv Manage Res. 2023;36:EP51\u201362. https:\/\/doi.org\/10.1177\/09514848221080687.","journal-title":"Health Serv Manage Res"},{"key":"859_CR64","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s00103-007-0367-7","volume":"50","author":"B Gaertner","year":"2007","unstructured":"Gaertner B, Enders M, Luft-Duchow C, Bocharov G, Modorow S, [Parvovirus. B-19 infections in pregnant women in day care facilities: health economic analysis of prohibition to employ seronegative women]. Parvovirus-B19-Infektionen bei Schwangeren in der Kinderbetreuung. Gesundheitsokonomische Anal eines Beschaftigungsverbots. 2007;50:1369\u201378. https:\/\/doi.org\/10.1007\/s00103-007-0367-7.","journal-title":"Gesundheitsokonomische Anal eines Beschaftigungsverbots"},{"key":"859_CR65","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jamda.2021.08.041","volume":"23","author":"S Gottschalk","year":"2022","unstructured":"Gottschalk S, K\u00f6nig H-H, Schwenk M, Nerz C, Becker C, Klenk J, et al. Cost-effective ness of a group vs individually delivered exercise program in community-dwelling per sons aged\u2009\u2265\u200970 years. J Am Med Dir Assoc. 2022;23:736\u2013e7426. https:\/\/doi.org\/10.1016\/j.jamda.2021.08.041.","journal-title":"J Am Med Dir Assoc"},{"key":"859_CR66","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1186\/s12885-023-10956-6","volume":"23","author":"LR Hallsson","year":"2023","unstructured":"Hallsson LR, Sroczynski G, Engel J, Siebert U. Decision-analytic evaluation of the comparative effectiveness and cost-effectiveness of strategies to prevent breast and ovarian cancer in German women with BRCA-1\/2 mutations. BMC Cancer. 2023;23:590. https:\/\/doi.org\/10.1186\/s12885-023-10956-6.","journal-title":"BMC Cancer"},{"key":"859_CR67","doi-asserted-by":"publisher","first-page":"7307","DOI":"10.1016\/j.vaccine.2007.08.017","volume":"25","author":"T Hammerschmidt","year":"2007","unstructured":"Hammerschmidt T, Bisanz H, Wutzler P. Universal mass vaccination against varicella in Germany using an MMRV combination vaccine with a two-dose schedule: An economic analysis. Vaccine. 2007;25:7307\u201312. https:\/\/doi.org\/10.1016\/j.vaccine.2007.08.017.","journal-title":"Vaccine"},{"key":"859_CR68","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s10198-015-0682-0","volume":"17","author":"J Hausler","year":"2016","unstructured":"Hausler J, Breyer F. Does diabetes prevention pay for itself? Evaluation of the M.O.B.I.L.I.S. program for obese persons. Eur J health economics: HEPAC : health Econ Prev care. 2016;17:379\u201389. https:\/\/doi.org\/10.1007\/s10198-015-0682-0.","journal-title":"Eur J health economics: HEPAC : health Econ Prev care"},{"key":"859_CR69","doi-asserted-by":"publisher","first-page":"7786","DOI":"10.1007\/s10389-008-0228-3","volume":"17","author":"P Hillemanns","year":"2009","unstructured":"Hillemanns P, Petry KU, Largeron N, McAllister R, Tolley K, B\u00fcsch K. Cost-effectiveness of a tetravalent human papillomavirus vaccine in Germany. J Public Health. 2009;17:7786. https:\/\/doi.org\/10.1007\/s10389-008-0228-3.","journal-title":"J Public Health"},{"key":"859_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12091045","author":"M Huang","year":"2024","unstructured":"Huang M, Weaver JP, Elbasha E, Weiss T, Banniettis N, Feemster K, et al. Cost-effectiveness analysis of routine childhood immunization with 20-valent versus 15-valent pneumococcal conjugate vaccines in Germany. Vaccines. 2024. https:\/\/doi.org\/10.3390\/vaccines12091045.","journal-title":"Vaccines"},{"key":"859_CR71","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/add.14062","volume":"113","author":"MB Huber","year":"2018","unstructured":"Huber MB, Prager M, Coyle K, Coyle D, Lester-George A, Trapero-Bertran M, et al. Cost effectiveness of increasing the reach of smoking cessation interventions in Germany: results from the EQUIPTMOD. Addiction (Abingdon England). 2018;113:52\u201364. https:\/\/doi.org\/10.1111\/add.14062.","journal-title":"Addiction (Abingdon England)"},{"key":"859_CR72","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/j.14645491.2007.02108.x","volume":"24","author":"A Icks","year":"2007","unstructured":"Icks A, Rathmann W, Haastert B, Gandjour A, Holle R, John J, et al. Clinical and cost-effectiveness of primary prevention of Type 2 diabetes in a \u2018real world\u2019 routine healthcare setting: model based on the KORA Survey 2000. Diabet medicine: J Br Diabet Association. 2007;24:473\u201380. https:\/\/doi.org\/10.1111\/j.14645491.2007.02108.x.","journal-title":"Diabet medicine: J Br Diabet Association"},{"key":"859_CR73","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1177\/0022034520979147","volume":"100","author":"M Jevdjevic","year":"2021","unstructured":"Jevdjevic M, Wijn SRW, Trescher AL, Nair R, Rovers M, Listl S. Front-of-package food labeling to reduce caries: economic evaluation. J Dent Res. 2021;100:472\u20138. https:\/\/doi.org\/10.1177\/0022034520979147.","journal-title":"J Dent Res"},{"key":"859_CR74","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1586\/erp.12.55","volume":"12","author":"Y Jiang","year":"2012","unstructured":"Jiang Y, Gauthier A, Annemans L, van der Linden M, Nicolas-Spony L, Bresse X. A public health and budget impact analysis of vaccinating at-risk adults and the elderly against pneumococcal diseases in Germany. Expert Rev PharmacoEcon Outcomes Res. 2012;12:631\u201343. https:\/\/doi.org\/10.1586\/erp.12.55.","journal-title":"Expert Rev PharmacoEcon Outcomes Res"},{"key":"859_CR75","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/13696998.2023.2290388","volume":"27","author":"K Joshi","year":"2024","unstructured":"Joshi K, Scholz S, Maschio M, Kohli M, Lee A, Fust K, et al. Clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2023 vaccines in Germany. J Med Econ. 2024;27:39\u201350. https:\/\/doi.org\/10.1080\/13696998.2023.2290388.","journal-title":"J Med Econ"},{"key":"859_CR76","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s10198-014-0624-2","volume":"16","author":"A Karmann","year":"2015","unstructured":"Karmann A, Jurack A, Lukas D. Recommendation of rotavirus vaccination and herd effect: a budget impact analysis based on German health insurance data. Eur J health economics: HEPAC: health Econ Prev care. 2015;16:719\u201331. https:\/\/doi.org\/10.1007\/s10198-014-0624-2.","journal-title":"Eur J health economics: HEPAC: health Econ Prev care"},{"key":"859_CR77","doi-asserted-by":"publisher","first-page":"e1004514","DOI":"10.1371\/journal.pmed.1004514","volume":"22","author":"A Kather","year":"2025","unstructured":"Kather A, Arefian H, Schneider C, Hartmann M, Runnebaum IB. Ovarian cancer prevention through opportunistic salpingectomy during abdominal surgeries: A cost-effective ness modeling study. PLoS Med. 2025;22:e1004514. https:\/\/doi.org\/10.1371\/journal.pmed.1004514.","journal-title":"PLoS Med"},{"key":"859_CR78","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1001\/archinternmed.2009.499","volume":"170","author":"W Kemmler","year":"2010","unstructured":"Kemmler W, von Stengel S, Engelke K, Haberle L, Kalender WA. Exercise effects on bone mineral density, falls, coronary risk factors, and health care costs in older women: the randomized controlled senior fitness and prevention (SEFIP) study. Arch Intern Med. 2010;170:179\u201385. https:\/\/doi.org\/10.1001\/archinternmed.2009.499.","journal-title":"Arch Intern Med"},{"key":"859_CR79","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10091386","author":"MA Kohli","year":"2022","unstructured":"Kohli MA, Maschio M, Cartier S, Mould-Quevedo J, Fricke F-U. The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany. Vaccines. 2022. https:\/\/doi.org\/10.3390\/vaccines10091386.","journal-title":"Vaccines"},{"key":"859_CR80","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s11606-022-07691-2","volume":"38","author":"C Konnopka","year":"2023","unstructured":"Konnopka C, B\u00fcchele G, Rothenbacher D, Roigk P, Rapp K, K\u00f6nig H-H. Health-economic evaluation of the German Osteoporotic Fracture Prevention Program in Rural Areas (OFRA): Mobility and Falls Prevention Classes, Examination of Bone Health, and Consultation on Safety in the Living Environment. J Gen Intern Med. 2023;38:641\u20137. https:\/\/doi.org\/10.1007\/s11606-022-07691-2.","journal-title":"J Gen Intern Med"},{"key":"859_CR81","doi-asserted-by":"publisher","DOI":"10.1186\/s13561-015-0054-6","author":"N Kotsopoulos","year":"2015","unstructured":"Kotsopoulos N, Connolly MP, Remy V. Quantifying the broader economic consequences of quadrivalent human papillomavirus (HPV) vaccination in Germany applying a government perspective framework. Health Econ Rev. 2015. https:\/\/doi.org\/10.1186\/s13561-015-0054-6.","journal-title":"Health Econ Rev"},{"key":"859_CR82","doi-asserted-by":"publisher","first-page":"e0197905","DOI":"10.1371\/journal.pone.0197905","volume":"13","author":"U Kuchenbecker","year":"2018","unstructured":"Kuchenbecker U, Chase D, Reichert A, Schiffner-Rohe J, Atwood M. Estimating the cost effectiveness of a sequential pneumococcal vaccination program for adults in Germany. PLoS ONE. 2018;13:e0197905. https:\/\/doi.org\/10.1371\/journal.pone.0197905.","journal-title":"PLoS ONE"},{"key":"859_CR83","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s10198-016-0770-9","volume":"18","author":"A Kuhlmann","year":"2017","unstructured":"Kuhlmann A, Graf von der Schulenburg J-M. Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany. Eur J Health Econ. 2017;18:273. https:\/\/doi.org\/10.1007\/s10198-016-0770-9. EP\u2009\u2013\u2009292.","journal-title":"Eur J Health Econ"},{"key":"859_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2191-1991-2-4","volume":"2","author":"A Kuhlmann","year":"2012","unstructured":"Kuhlmann A, Theidel U, Pletz MW, Graf von der Schulenburg J-M. Potential cost-effectiveness and benefit-cost ratios of adult Pneumococcal vaccination in Germany. Health Econ Rev. 2012;2:1. https:\/\/doi.org\/10.1186\/2191-1991-2-4. EP\u2009\u2013\u200913.","journal-title":"Health Econ Rev"},{"key":"859_CR85","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1080\/14760584.2023.2262575","volume":"22","author":"F K\u00fchne","year":"2023","unstructured":"K\u00fchne F, Achtert K, P\u00fcschner F, Urbanski-Rini D, Schiller J, Mahar E, et al. Cost-effectiveness of use of 20-valent pneumococcal conjugate vaccine among adults in Germany. Expert Rev Vaccines. 2023;22:921\u201332. https:\/\/doi.org\/10.1080\/14760584.2023.2262575.","journal-title":"Expert Rev Vaccines"},{"key":"859_CR86","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/14737167.2016.1208087","volume":"17","author":"N Largeron","year":"2017","unstructured":"Largeron N, Petry KU, Jacob J, Bianic F, Anger D, Uhart M. An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany. Expert Rev PharmacoEcon Outcomes Res. 2017;17:85\u201398. https:\/\/doi.org\/10.1080\/14737167.2016.1208087.","journal-title":"Expert Rev PharmacoEcon Outcomes Res"},{"key":"859_CR87","doi-asserted-by":"publisher","first-page":"3673","DOI":"10.1016\/j.vaccine.2008.04.068","volume":"26","author":"GM Lee","year":"2008","unstructured":"Lee GM, Riffelmann M, von Wirsing CH. Cost-effectiveness of adult pertussis vaccination in Germany. Vaccine. 2008;26:3673. https:\/\/doi.org\/10.1016\/j.vaccine.2008.04.068. EP\u2009\u2013\u20093679.","journal-title":"Vaccine"},{"key":"859_CR88","doi-asserted-by":"publisher","first-page":"EP7","DOI":"10.1007\/s10198-006-0013-6","volume":"9","author":"A Lloyd","year":"2008","unstructured":"Lloyd A, Patel N, Scott DA, Runge C, Claes C, Rose M. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: Considering a high-risk population and herd immunity effects. Eur J Health Econ. 2008;9:EP7\u201315. https:\/\/doi.org\/10.1007\/s10198-006-0013-6.","journal-title":"Eur J Health Econ"},{"key":"859_CR89","doi-asserted-by":"publisher","first-page":"e4445","DOI":"10.1136\/bmj.e4445","volume":"345","author":"AK Lugner","year":"2012","unstructured":"Lugner AK, van Boven M, de Vries R, Postma MJ, Wallinga J. Cost effectiveness of vaccination against pandemic influenza in European countries: mathematical modelling analysis. BMJ (Clinical Res ed). 2012;345:e4445. https:\/\/doi.org\/10.1136\/bmj.e4445.","journal-title":"BMJ (Clinical Res ed)"},{"key":"859_CR90","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/j.1399-3038.2012.01304.x","volume":"23","author":"J Mertens","year":"2012","unstructured":"Mertens J, Stock S, L\u00fcngen M, von Berg A, Kr\u00e4mer U, Filipiak-Pittroff B, et al. Is prevention of atopic eczema with hydrolyzed formulas cost-effective? A health economic evaluation from Germany. Pediatr Allergy Immunol. 2012;23:597\u2013604. https:\/\/doi.org\/10.1111\/j.1399-3038.2012.01304.x.","journal-title":"Pediatr Allergy Immunol"},{"key":"859_CR91","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1111\/j.15325415.2005.00490.x","volume":"53","author":"G Meyer","year":"2005","unstructured":"Meyer G, Wegscheider K, Kersten JF, Icks A, Muhlhauser I. Increased use of hip protectors in nursing homes: economic analysis of a cluster randomized, controlled trial. J Am Geriatr Soc. 2005;53:2153\u20138. https:\/\/doi.org\/10.1111\/j.15325415.2005.00490.x.","journal-title":"J Am Geriatr Soc"},{"key":"859_CR92","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s10198-003-0187-0","volume":"4","author":"T Mittendorf","year":"2003","unstructured":"Mittendorf T, Petry KU, Iftner T, Greiner W, von Schulenburg JM. der. Economic evaluation of human papillomavirus screening in Germany. Eur J Health Econ. 2003;4:209\u201315. https:\/\/doi.org\/10.1007\/s10198-003-0187-0.","journal-title":"Eur J Health Econ"},{"key":"859_CR93","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2058304","author":"D Molnar","year":"2022","unstructured":"Molnar D, Anastassopoulou A, Nautrup BP, Schmidt-Ott R, Eichner M, Schwehm M, et al. Cost-utility analysis of increasing uptake of universal seasonal quadrivalent influenza vaccine (QIV) in children aged 6 months and older in Germany. Hum Vaccines Immunotherapeutics. 2022. https:\/\/doi.org\/10.1080\/21645515.2022.2058304.","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"859_CR94","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s10198-014-0605-5","volume":"16","author":"D Muller","year":"2015","unstructured":"Muller D, Borsi L, Stracke C, Stock S, Stollenwerk B. Cost-effectiveness of a multifactorial fracture prevention program for elderly people admitted to nursing homes. Euro pean J health economics: HEPAC: health Econ Prev care. 2015;16:517\u201327. https:\/\/doi.org\/10.1007\/s10198-014-0605-5.","journal-title":"Euro pean J health economics: HEPAC: health Econ Prev care"},{"key":"859_CR95","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s10198-01901038-1","volume":"20","author":"D Muller","year":"2019","unstructured":"Muller D, Danner M, Schmutzler R, Engel C, Wassermann K, Stollenwerk B, et al. Economic modeling of risk-adapted screen-and-treat strategies in women at high risk for breast or ovarian cancer. Eur J health economics: HEPAC: health Econ Prev care. 2019;20:739\u201350. https:\/\/doi.org\/10.1007\/s10198-01901038-1.","journal-title":"Eur J health economics: HEPAC: health Econ Prev care"},{"key":"859_CR96","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12101165","author":"M M\u00fcller","year":"2024","unstructured":"M\u00fcller M, Lintener H, Henkel V, Pilz A, Halsby K, Malerczyk C, et al. Does the Vaccination against tick-borne encephalitis offer good value for money for incidence rates below the WHO threshold for endemicity? A case study for Germany. Vaccines. 2024. https:\/\/doi.org\/10.3390\/vaccines12101165.","journal-title":"Vaccines"},{"key":"859_CR97","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1002\/1878-0261.12924","volume":"15","author":"T Niedermaier","year":"2021","unstructured":"Niedermaier T, Gredner T, Kuznia S, Schottker B, Mons U, Brenner H. Vitamin D supple mentation to the older adult population in Germany has the cost-saving potential of preventing almost 30.000 cancer deaths per year. Mol Oncol. 2021;15:1986\u201394. https:\/\/doi.org\/10.1002\/1878-0261.12924.","journal-title":"Mol Oncol"},{"key":"859_CR98","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2024-004382","author":"K Ogurtsova","year":"2024","unstructured":"Ogurtsova K, Laxy M, Emmert-Fees K, Dintsios C-M, Zhang P, Icks A. National health and economic impact of a lifestyle program to prevent type 2 diabetes mellitus in Germany: a simulation study. BMJ open diabetes Res care. 2024. https:\/\/doi.org\/10.1136\/bmjdrc-2024-004382.","journal-title":"BMJ open diabetes Res care"},{"key":"859_CR99","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1080\/21645515.2015.1011561","volume":"11","author":"E Pr\u00e9aud","year":"2015","unstructured":"Pr\u00e9aud E, Uhart M, B\u00f6hm K, Aidelsburger P, Anger D, Bianic F, Largeron N. Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post herpetic neuralgia in adults aged 50 and over in Germany. Hum vaccines immunotherapeutics. 2015;11:884\u201396. https:\/\/doi.org\/10.1080\/21645515.2015.1011561.","journal-title":"Hum vaccines immunotherapeutics"},{"key":"859_CR100","doi-asserted-by":"publisher","DOI":"10.3389\/ijph.2024.1607218","author":"H Roesner","year":"2024","unstructured":"Roesner H, Neusius T, Strametz R, Mira JJ. Economic Value of Peer Support Program in German Hospitals. Int J Public Health. 2024. https:\/\/doi.org\/10.3389\/ijph.2024.1607218.","journal-title":"Int J PUBLIC HEALTH"},{"key":"859_CR101","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1055\/s-2003-43100","volume":"128","author":"R Rychlik","year":"2003","unstructured":"Rychlik R, Heinen-Kammerer T, Rusche H, Piercy J, Scuffham P, Zollner Y. [Cost-effectiveness of prophylaxis and treatment of influenza]. Dtsch Med Wochenschr. 2003;128:2267\u201370. https:\/\/doi.org\/10.1055\/s-2003-43100.","journal-title":"Dtsch Med Wochenschr"},{"key":"859_CR102","doi-asserted-by":"publisher","first-page":"EP1874","DOI":"10.1017\/S1368980015003171","volume":"20","author":"A Sandmann","year":"2017","unstructured":"Sandmann A, Amling M, Barvencik F, Konig H-H, Bleibler F. Economic evaluation of vitamin D and calcium food fortification for fracture prevention in Germany. Public Health Nutr. 2017;20:EP1874\u20131883. https:\/\/doi.org\/10.1017\/S1368980015003171.","journal-title":"Public Health Nutr"},{"key":"859_CR103","doi-asserted-by":"publisher","first-page":"EP132","DOI":"10.36469\/001C.90651","volume":"10","author":"R Saunders","year":"2023","unstructured":"Saunders R, Torres RT, Reuter H, Gibson S. A Health economic analysis exploring the cost consequence of using a surgical site infection prevention bundle for hip and knee arthroplasty in Germany. J Health Econ Outcomes Res. 2023;10:EP132\u2013140. https:\/\/doi.org\/10.36469\/001C.90651.","journal-title":"J Health Econ Outcomes Res"},{"key":"859_CR104","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-021-02329-0","author":"B Scheckel","year":"2021","unstructured":"Scheckel B, Stock S, M\u00fcller D. Cost-effectiveness of group-based exercise to prevent falls in elderly community-dwelling people. BMC Geriatr. 2021. https:\/\/doi.org\/10.1186\/s12877-021-02329-0.","journal-title":"BMC Geriatr"},{"key":"859_CR105","doi-asserted-by":"publisher","unstructured":"Schobert D, Remy V, Schoeffski O. Cost-effectiveness of vaccination with a quadrivalent HPV vaccine in Germany using a dynamic transmission model. Health Econ Rev. 2012;2. https:\/\/doi.org\/10.1186\/2191-1991-2-19. :1 EP\u2009\u2013\u200910.","DOI":"10.1186\/2191-1991-2-19"},{"key":"859_CR106","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40121-021-00573-w","volume":"11","author":"S Scholz","year":"2022","unstructured":"Scholz S, Schwarz M, Beck E, Meszaros K, Schneider M, Ultsch B, Greiner W. Public health impact and cost-effectiveness analysis of routine infant 4CMenB vaccination in Germany to prevent serogroup B invasive meningococcal disease. Infect Dis Therapy. 2022;11:367\u201387. https:\/\/doi.org\/10.1007\/s40121-021-00573-w.","journal-title":"Infect Dis Therapy"},{"key":"859_CR107","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.breast.2017.02.008","volume":"32","author":"MG Schrauder","year":"2017","unstructured":"Schrauder MG, Brunel-Geuder L, Haberle L, Wunderle M, Hoyer J, Reis A, et al. Cost-effectiveness of risk-reducing surgeries in preventing hereditary breast and ovarian cancer. Breast (Edinburgh Scotland). 2017;32:186\u201391. https:\/\/doi.org\/10.1016\/j.breast.2017.02.008.","journal-title":"Breast (Edinburgh Scotland)"},{"key":"859_CR108","doi-asserted-by":"publisher","first-page":"e66454","DOI":"10.1371\/journal.pone.0066454","volume":"8","author":"CA Schuetz","year":"2013","unstructured":"Schuetz CA, Alperin P, Guda S, van Herick A, Cariou B, Eddy D, et al. A standardized vascular disease health check in Europe: a cost-effectiveness analysis. PLoS ONE. 2013;8:e66454. https:\/\/doi.org\/10.1371\/journal.pone.0066454.","journal-title":"PLoS ONE"},{"key":"859_CR109","doi-asserted-by":"publisher","first-page":"104635","DOI":"10.1016\/j.jdent.2023.104635","volume":"137","author":"F Schwendicke","year":"2023","unstructured":"Schwendicke F, Bombeck L. Cost-effectiveness of school-based caries screening using transillumination. J Dent. 2023;137:104635. https:\/\/doi.org\/10.1016\/j.jdent.2023.104635.","journal-title":"J Dent"},{"key":"859_CR110","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1159\/000458729","volume":"51","author":"F Schwendicke","year":"2017","unstructured":"Schwendicke F, Stolpe M. In-office application of Fluoride Gel or Varnish: cost-effectiveness and expected value of perfect information analysis. Caries Res. 2017;51:231\u20139. https:\/\/doi.org\/10.1159\/000458729.","journal-title":"Caries Res"},{"key":"859_CR111","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1111\/jcpe.12775","volume":"44","author":"F Schwendicke","year":"2017","unstructured":"Schwendicke F, Stolpe M, Muller F. Professional oral health care for preventing nursing home-acquired pneumonia: A cost-effectiveness and value of information analysis. J Clin Periodontol. 2017;44:1236\u201344. https:\/\/doi.org\/10.1111\/jcpe.12775.","journal-title":"J Clin Periodontol"},{"key":"859_CR112","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1016\/S0264-410X(02)00154-8","volume":"20","author":"PA Scuffham","year":"2002","unstructured":"Scuffham PA, West PA. Economic evaluation of strategies for the control and management of influenza in Europe. Vaccine. 2002;20:2562. https:\/\/doi.org\/10.1016\/S0264-410X(02)00154-8. EP\u2009\u2013\u20092578.","journal-title":"Vaccine"},{"key":"859_CR113","doi-asserted-by":"publisher","first-page":"243","DOI":"10.4161\/hv.18519","volume":"8","author":"P Soergel","year":"2012","unstructured":"Soergel P, Makowski L, Schippert C, Staboulidou I, Hille U, Hillemanns P. The cost efficiency of HPV vaccines is significantly underestimated due to omission of conisation associated prematurity with neonatal mortality and morbidity. Hum vaccines immunotherapeutics. 2012;8:243\u201351. https:\/\/doi.org\/10.4161\/hv.18519.","journal-title":"Hum vaccines immunotherapeutics"},{"key":"859_CR114","doi-asserted-by":"publisher","DOI":"10.3390\/nu11071653","author":"D Sonntag","year":"2019","unstructured":"Sonntag D, de Bock F, Totzauer M, Koletzko B. Assessing the lifetime cost-effectiveness of low-protein infant formula as early obesity prevention strategy: the CHOP randomized trial. Nutrients. 2019. https:\/\/doi.org\/10.3390\/nu11071653.","journal-title":"Nutrients"},{"key":"859_CR115","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/j.16000722.2008.00524.x","volume":"116","author":"CH Splieth","year":"2008","unstructured":"Splieth CH, Flessa S. Modelling lifelong costs of caries with and without fluoride use. Eur J Oral Sci. 2008;116:164\u20139. https:\/\/doi.org\/10.1111\/j.16000722.2008.00524.x.","journal-title":"Eur J Oral Sci"},{"key":"859_CR116","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2147\/JHL.S498789","volume":"17","author":"R Strametz","year":"2025","unstructured":"Strametz R, Roesner H, Neusius T, Wiesenhuetter I, Bushuven S, Mira JJ, et al. The Economic implications of psychosocial peer support for health workers in German Hospitals. J Healthc Leadersh. 2025;17:15\u201322. https:\/\/doi.org\/10.2147\/JHL.S498789.","journal-title":"J Healthc Leadersh"},{"key":"859_CR117","doi-asserted-by":"publisher","first-page":"EP54","DOI":"10.1016\/j.jinf.2011.10.015","volume":"64","author":"DR Strutton","year":"2012","unstructured":"Strutton DR, Farkouh RA, Earnshaw SR, Hwang S, Theidel U, Kontodimas S, et al. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands. J Infect. 2012;64:EP54\u201367. https:\/\/doi.org\/10.1016\/j.jinf.2011.10.015.","journal-title":"J Infect"},{"key":"859_CR118","doi-asserted-by":"publisher","unstructured":"Szucs TD, Smala A, Berger K, Windorfer A. Economic evaluation of different vaccination strategies against hepatitis B in children and adolescents. Gesundheitsokonomische Evaluation des Screenings auf APC-Resistenz (Mutation Leiden) bei Neuanwenderinnen von Ovulationshemmern. 1998;93:EP468\u2013477. https:\/\/doi.org\/10.1007\/bf03042596","DOI":"10.1007\/bf03042596"},{"key":"859_CR119","doi-asserted-by":"publisher","first-page":"EP1333","DOI":"10.1007\/s40121-024-00977-4","volume":"13","author":"A Ta","year":"2024","unstructured":"Ta A, Kuhne F, Laurenz M, von Eiff C, Warren S, Perdrizet J. Cost-effectiveness of PCV20 to prevent pneumococcal disease in the pediatric population: A German societal perspective analysis. Infect Dis Therapy. 2024;13:EP1333\u20131358. https:\/\/doi.org\/10.1007\/s40121-024-00977-4.","journal-title":"Infect Dis Therapy"},{"key":"859_CR120","doi-asserted-by":"publisher","first-page":"G23","DOI":"10.1016\/j.vaccine.2010.06.016","volume":"28","author":"SE Talbird","year":"2010","unstructured":"Talbird SE, Taylor TN, Knoll S, Frostad CR, Garcia Marti S. Outcomes and costs as sociated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries. Vaccine. 2010;28:G23\u20139. https:\/\/doi.org\/10.1016\/j.vaccine.2010.06.016.","journal-title":"Vaccine"},{"key":"859_CR121","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s004310050837","volume":"157","author":"G Tormans","year":"1998","unstructured":"Tormans G, van Doorslaer E, van Damme P, Clara R, Schmitt HJ. Economic evaluation of pertussis prevention by whole-cell and acellular vaccine in Germany. Eur J Pediatrics. 1998;157:395\u2013401. https:\/\/doi.org\/10.1007\/s004310050837.","journal-title":"Eur J Pediatrics"},{"key":"859_CR122","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1186\/1472-6963-13-359","volume":"13","author":"B Ultsch","year":"2013","unstructured":"Ultsch B, Weidemann F, Reinhold T, Siedler A, Krause G, Wichmann O. Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany. BMC Health Serv Res. 2013;13:359. https:\/\/doi.org\/10.1186\/1472-6963-13-359.","journal-title":"BMC Health Serv Res"},{"key":"859_CR123","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1080\/21645515.2018.1509645","volume":"15","author":"D van Oorschot","year":"2019","unstructured":"van Oorschot D, Anastassopoulou A, Poulsen Nautrup B, Varghese L, von Krempelhuber A, Neine M, et al. Cost-effectiveness of the recombinant zoster vaccine in the German population aged\u2009>\u2009=\u200960 years old. Hum vaccines immunotherapeutics. 2019;15:34\u201344. https:\/\/doi.org\/10.1080\/21645515.2018.1509645.","journal-title":"Hum vaccines immunotherapeutics"},{"key":"859_CR124","first-page":"EP248","volume":"41","author":"A Windorfer","year":"2006","unstructured":"Windorfer A, Ryan J, Zoellner Y. Economic assessment of vaccination against influenza at the workplace in Germany. Arbeitsmedizin Sozialmedizin Umweltmedizin. 2006;41:EP248\u2013253.","journal-title":"Arbeitsmedizin Sozialmedizin Umweltmedizin"},{"key":"859_CR125","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00430-002-0123-4","volume":"191","author":"P Wutzler","year":"2002","unstructured":"Wutzler P, Neiss A, Banz K, Goertz A, Bisanz H. Can varicella be eliminated by vaccination? Potential clinical and economic effects of universal childhood varicella immunisation in Germany. Med Microbiol Immunol. 2002;191:89\u201396. https:\/\/doi.org\/10.1007\/s00430-002-0123-4.","journal-title":"Med Microbiol Immunol"},{"key":"859_CR126","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1080\/00016357.2018.1487994","volume":"76","author":"S Zimmer","year":"2018","unstructured":"Zimmer S, Spyra A, Kreimendahl F, Blaich C, Rychlik R. Elevating the use of sugar free chewing gum in Germany: cost saving and caries prevention. Acta Odontol Scand. 2018;76:407\u201314. https:\/\/doi.org\/10.1080\/00016357.2018.1487994.","journal-title":"Acta Odontol Scand"},{"key":"859_CR127","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/1472-6963-14-263","volume":"14","author":"M Aljutaili","year":"2014","unstructured":"Aljutaili M, Becker C, Witt S, Holle R, Leidl R, Block M, et al. Should health insurers target prevention of cardiovascular disease? A cost-effectiveness analysis of an individualised programme in Germany based on routine data. BMC Health Serv Res. 2014;14:263. https:\/\/doi.org\/10.1186\/1472-6963-14-263.","journal-title":"BMC Health Serv Res"},{"key":"859_CR128","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2147\/ceor.s234385","volume":"12","author":"SF Armstrong","year":"2020","unstructured":"Armstrong SF, Guest JF. Cost-effectiveness and cost-benefit of cervical cancer screening with liquid based cytology compared with conventional cytology in Germany. ClinicoEconomics Outcomes Res. 2020;12:153. https:\/\/doi.org\/10.2147\/ceor.s234385. EP\u2009\u2013\u2009166.","journal-title":"ClinicoEconomics Outcomes Res"},{"key":"859_CR129","doi-asserted-by":"publisher","first-page":"e0217213","DOI":"10.1371\/journal.pone.0217213","volume":"14","author":"M Arnold","year":"2019","unstructured":"Arnold M, Pfeifer K, Quante AS. Is risk-stratified breast cancer screening economically efficient in Germany? PLoS ONE. 2019;14:e0217213. https:\/\/doi.org\/10.1371\/journal.pone.0217213.","journal-title":"PLoS ONE"},{"key":"859_CR130","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s003470050230","volume":"95","author":"JC Barry","year":"1998","unstructured":"Barry JC, Hartmann A, Pongs UM, Jockel M. [Model for cost-benefit relations of amblyopia screening]. Modell fur das Nutzen-Kosten-Verhaltnis des Amblyopie-Screenings. 1998;95:19\u201327. https:\/\/doi.org\/10.1007\/s003470050230.","journal-title":"Modell fur das Nutzen-Kosten-Verhaltnis des Amblyopie-Screenings"},{"key":"859_CR131","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1080\/00365521.2017.1390599","volume":"53","author":"C Barth","year":"2018","unstructured":"Barth C, Neusser S, Biermann J, Wasem J, Berg T, Wiegand J, et al. Budget impact analysis on the introduction of a guideline based hepatitis B and C screening into a routine check-up in the German primary care setting. Scand J Gastroenterol. 2018;53:76\u201382. https:\/\/doi.org\/10.1080\/00365521.2017.1390599.","journal-title":"Scand J Gastroenterol"},{"key":"859_CR132","first-page":"281","volume":"55","author":"L Batzdorfer","year":"2002","unstructured":"Batzdorfer L, Klippel U, Schwanitz HJ. Cost-benefit analysis: prevention of occupational dermatoses in geriatric nursing. Pflege-Zeitschrift. 2002;55:281\u20135.","journal-title":"Pflege-Zeitschrift"},{"key":"859_CR133","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.healthpol.2015.01.012","volume":"119","author":"C Becker","year":"2015","unstructured":"Becker C, Holle R, Stollenwerk B. The excess health care costs of KardioPro, an integrated care program for coronary heart disease prevention. Health Policy. 2015;119:778\u201386. https:\/\/doi.org\/10.1016\/j.healthpol.2015.01.012.","journal-title":"Health Policy"},{"key":"859_CR134","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/ijc.2910580502","volume":"58","author":"PM Beemsterboer","year":"1994","unstructured":"Beemsterboer PM, de Koning HJ, Warmerdam PG, Boer R, Swart E, Dierks ML, Robra BP. Prediction of the effects and costs of breast-cancer screening in Germany. Int J Cancer. 1994;58:623\u20138. https:\/\/doi.org\/10.1002\/ijc.2910580502.","journal-title":"Int J Cancer"},{"key":"859_CR135","doi-asserted-by":"publisher","DOI":"10.1186\/s13561-020-00274-z","author":"R Birkemeyer","year":"2020","unstructured":"Birkemeyer R, M\u00fcller A, Wahler S, Graf von der Schulenburg J-M. A cost-effectiveness analysis model of Preventicus atrial fibrillation screening from the point of view of statutory health insurance in Germany. Health Econ Rev. 2020. https:\/\/doi.org\/10.1186\/s13561-020-00274-z.","journal-title":"Health Econ Rev"},{"key":"859_CR136","doi-asserted-by":"publisher","first-page":"EP35","DOI":"10.1183\/09031936.06.00011806","volume":"28","author":"R Diel","year":"2006","unstructured":"Diel R, Nienhaus A, Lange C, Schaberg T. Cost-optimisation of screening for latent tuberculosis in close contacts. Eur Respir J. 2006;28:EP35\u201344. https:\/\/doi.org\/10.1183\/09031936.06.00011806.","journal-title":"Eur Respir J"},{"key":"859_CR137","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1016\/j.rmed.2009.07.008","volume":"103","author":"R Diel","year":"2009","unstructured":"Diel R, Schaberg T, Loddenkemper R, Welte T, Nienhaus A. Enhanced cost-benefit analysis of strategies for LTBI screening and INH chemoprevention in Germany. Respir Med. 2009;103:1838\u201353. https:\/\/doi.org\/10.1016\/j.rmed.2009.07.008.","journal-title":"Respir Med"},{"key":"859_CR138","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ijheh.2007.06.001","volume":"211","author":"R Diller","year":"2008","unstructured":"Diller R, Sonntag AK, Mellmann A, Grevener K, Senninger N, Kipp F, Friedrich AW. Evidence for cost reduction based on pre-admission MRSA screening in general surgery. Int J Hyg Environ Health. 2008;211:205\u201312. https:\/\/doi.org\/10.1016\/j.ijheh.2007.06.001.","journal-title":"Int J Hyg Environ Health"},{"key":"859_CR139","doi-asserted-by":"publisher","first-page":"iv19","DOI":"10.1093\/eurheartjsupp\/suae076","volume":"26","author":"M Eklund","year":"2024","unstructured":"Eklund M, Bernfort L, Appelberg K, Engler D, Schnabel RB, Martinez C, et al. The budget impact of implementing atrial fibrillation-screening in European countries. Eur Heart J Supplement. 2024;26:iv19\u201332. https:\/\/doi.org\/10.1093\/eurheartjsupp\/suae076.","journal-title":"Eur Heart J Supplement"},{"key":"859_CR140","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1093\/jphsr\/rmac008","volume":"13","author":"R Frankenberger","year":"2022","unstructured":"Frankenberger R, Arweiler NB, Sorsa TA, Volland G, Gassmann G, Fietz C, et al. Health economic potential of oral aMMP-8 biomarker diagnostics for personalised prevention of periodontal and peri-implant diseases. J Pharm HEALTH Serv Res. 2022;13:52\u201360. https:\/\/doi.org\/10.1093\/jphsr\/rmac008.","journal-title":"J Pharm HEALTH Serv Res"},{"key":"859_CR141","doi-asserted-by":"publisher","first-page":"EP259","DOI":"10.1097\/00006324-200303000-00016","volume":"80","author":"A Gandjour","year":"2003","unstructured":"Gandjour A, Schlichtherle S, Neugebauer A, Russmann W, Lauterbach KW. A cost effectiveness model of screening strategies for amblyopia and risk factors and its application in a German setting. Optom Vis Sci. 2003;80:EP259\u2013269. https:\/\/doi.org\/10.1097\/00006324-200303000-00016.","journal-title":"Optom Vis Sci"},{"key":"859_CR142","doi-asserted-by":"publisher","first-page":"108895","DOI":"10.1111\/j.1524-4733.2008.00393.x","volume":"11","author":"A Gandjour","year":"2008","unstructured":"Gandjour A, Weyler E-J. Cost-effectiveness of preventing hip fractures by hip protectors in elderly institutionalized residents in Germany. Value health: J Int Soc Pharmacoeconomics Outcomes Res. 2008;11:108895. https:\/\/doi.org\/10.1111\/j.1524-4733.2008.00393.x.","journal-title":"Value health: J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"859_CR143","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12913-021-07277-4","volume":"22","author":"A Gandjour","year":"2022","unstructured":"Gandjour A. Benefits, risks, and cost-effectiveness of COVID-19 self-tests from a consumer\u2019s perspective. BMC Health Serv Res. 2022;22:47. https:\/\/doi.org\/10.1186\/s12913-021-07277-4.","journal-title":"BMC Health Serv Res"},{"key":"859_CR144","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.healthpol.2019.08.015","volume":"123","author":"F Gansen","year":"2019","unstructured":"Gansen F, Severin F, Schleidgen S, Marckmann G, Rogowski W. Lethal privacy: Quantifying life years lost if the right to informational self-determination guides genetic screening for Lynch syndrome. Health Policy. 2019;123:1004. https:\/\/doi.org\/10.1016\/j.healthpol.2019.08.015. EP\u2009\u2013\u20091010.","journal-title":"Health Policy"},{"key":"859_CR145","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1055\/s-2007-1022526","volume":"70","author":"A Hagen","year":"2008","unstructured":"Hagen A, Hessabi HK, Gorenoi V, Schonermark MP. [Cost-effectiveness evaluation of predictive molecular diagnostics using the example of hereditary non-polyposis colorectal cancer (HNPCC)]. Kosteneffektivitatsbewertung Pradiktiver Molekulardiagnostik am Beispiel des Hereditaren Nichtpolyposen Kolorektalkarzinoms (HNPCC). 2008;70:18\u201327. https:\/\/doi.org\/10.1055\/s-2007-1022526.","journal-title":"Kosteneffektivitatsbewertung Pradiktiver Molekulardiagnostik am Beispiel des Hereditaren Nichtpolyposen Kolorektalkarzinoms (HNPCC)"},{"key":"859_CR146","doi-asserted-by":"publisher","unstructured":"Heinemann M, Bohnert A. [Hearing screening in newborn infants. Comparative studies and cost analysis with different instruments]. H\u00f6rscreening bei Neugeborenen. Vergleichende Untersuchungen und Kostenanalysen mit verschiedenen Ger\u00e4ten. 2000;79:453\u20138. https:\/\/doi.org\/10.1055\/s-2000-5911","DOI":"10.1055\/s-2000-5911"},{"key":"859_CR147","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s00198-012-2075-x","volume":"24","author":"S Heinrich","year":"2013","unstructured":"Heinrich S, Rapp K, Stuhldreher N, Rissmann U, Becker C, Konig H-H. Cost-effectiveness of a multifactorial fall prevention program in nursing homes. Osteoporos international: J established as result cooperation between Eur Foundation Osteoporos Natl Osteoporos Foundation USA. 2013;24:1215\u201323. https:\/\/doi.org\/10.1007\/s00198-012-2075-x.","journal-title":"Osteoporos international: J established as result cooperation between Eur Foundation Osteoporos Natl Osteoporos Foundation USA"},{"key":"859_CR148","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.lungcan.2018.07.036","volume":"124","author":"F Hofer","year":"2018","unstructured":"Hofer F, Kauczor H-U, Stargardt T. Cost-utility analysis of a potential lung cancer screening program for a high-risk population in Germany: A modelling approach. Lung cancer (Amsterdam Netherlands). 2018;124:189\u201398. https:\/\/doi.org\/10.1016\/j.lungcan.2018.07.036.","journal-title":"Lung cancer (Amsterdam Netherlands)"},{"key":"859_CR149","doi-asserted-by":"publisher","DOI":"10.1186\/s13756015-0093-0","author":"C H\u00fcbner","year":"2015","unstructured":"H\u00fcbner C, H\u00fcbner NO, Wegner C, Flessa S. Impact of different diagnostic technologies for MRSA admission screening in hospitals - a decision tree analysis. ANTIMICRO BIAL Resist Infect CONTROL. 2015. https:\/\/doi.org\/10.1186\/s13756015-0093-0.","journal-title":"ANTIMICRO BIAL Resist Infect CONTROL"},{"key":"859_CR150","doi-asserted-by":"publisher","first-page":"EP2120","DOI":"10.2337\/diacare.27.9.2120","volume":"27","author":"A Icks","year":"2004","unstructured":"Icks A, Haastert B, Gandjour A, John J, Lowel H, Holle R, et al. Cost-effectiveness analysis of different screening procedures for type 2 diabetes: The KORA survey 2000. Diabetes Care. 2004;27:EP2120\u20132128. https:\/\/doi.org\/10.2337\/diacare.27.9.2120.","journal-title":"Diabetes Care"},{"key":"859_CR151","doi-asserted-by":"publisher","first-page":"e0262227","DOI":"10.1371\/journal.pone.0262227","volume":"17","author":"P Kairys","year":"2022","unstructured":"Kairys P, Frese T, Voigt P, Horn J, Girndt M, Mikolajczyk R. Development of the simulation-based German albuminuria screening model (S-GASM) for estimating the cost-effectiveness of albuminuria screening in Germany. PLoS ONE. 2022;17:e0262227. https:\/\/doi.org\/10.1371\/journal.pone.0262227.","journal-title":"PLoS ONE"},{"key":"859_CR152","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1055\/s-2000-10859","volume":"62","author":"HH Konig","year":"2000","unstructured":"Konig HH, Barry JC, Leidl R, Zrenner E. [Cost effectiveness of mass orthoptic screening in kindergarten for early detection of developmental vision disorders]. Kosteneffektivitat der orthoptischen Reihenuntersuchung im Kindergarten zur Fr\u00fcherkennung. visueller Entwicklungsstorungen. 2000;62:196\u2013206. https:\/\/doi.org\/10.1055\/s-2000-10859.","journal-title":"visueller Entwicklungsstorungen"},{"key":"859_CR153","first-page":"EP3209","volume":"43","author":"H-H Konig","year":"2002","unstructured":"Konig H-H, Barry J-C, Leidl R, Zrenner E. Economic evaluation of orthoptic screening: Results of a field study in 121 German kindergartens. Invest Ophthalmol Visual Sci. 2002;43:EP3209\u20133215.","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"859_CR154","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1542\/peds.109.4.e59","volume":"109","author":"H-H Konig","year":"2002","unstructured":"Konig H-H, Barry J-C. Economic evaluation of different methods of screening for amblyopia in kindergarten. Pediatrics. 2002;109:e59. https:\/\/doi.org\/10.1542\/peds.109.4.e59.","journal-title":"Pediatrics"},{"key":"859_CR155","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1542\/peds.113.2.e95","volume":"113","author":"H-H Konig","year":"2004","unstructured":"Konig H-H, Barry J-C. Cost-utility analysis of orthoptic screening in kindergarten: a Markov model based on data from Germany. Pediatrics. 2004;113:e95\u2013108. https:\/\/doi.org\/10.1542\/peds.113.2.e95.","journal-title":"Pediatrics"},{"key":"859_CR156","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1186\/s12879-0194524-z","volume":"19","author":"C Krauth","year":"2019","unstructured":"Krauth C, Rossol S, Orts\u00e4ter G, Kautz A, Kr\u00fcger K, Herder B, Stahmeyer JT. Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies. BMC Infect Dis. 2019;19:1019. https:\/\/doi.org\/10.1186\/s12879-0194524-z.","journal-title":"BMC Infect Dis"},{"key":"859_CR157","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1111\/ced.14550","volume":"46","author":"M Krensel","year":"2021","unstructured":"Krensel M, Andrees V, Mohr N, Hischke S. Costs of routine skin cancer screening in Germany: a claims data analysis. Clin Exp Dermatol. 2021;46:842 EP-850. https:\/\/doi.org\/10.1111\/ced.14550.","journal-title":"Clin Exp Dermatol"},{"key":"859_CR158","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s11657-018-0535-4","volume":"13","author":"C Kunigkeit","year":"2018","unstructured":"Kunigkeit C, Stock S, Muller D. Cost-effectiveness of a home safety intervention to prevent falls in impaired elderly people living in the community. Archives Osteoporos. 2018;13:122. https:\/\/doi.org\/10.1007\/s11657-018-0535-4.","journal-title":"Archives Osteoporos"},{"key":"859_CR159","doi-asserted-by":"publisher","unstructured":"Ladabaum U, Alvarez-Osorio L, Rosch T, Brueggenjuergen B. Cost-effectiveness of colorectal cancer screening in Germany: Current endoscopic and fecal testing strategies versus plasma methylated Septin 9 DNA 1. Endoscopy Int Open. 2014;2. https:\/\/doi.org\/10.1055\/s-0034-1377182. E96 EP - E104.","DOI":"10.1055\/s-0034-1377182"},{"key":"859_CR160","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12884-016-0966-0","volume":"16","author":"AE Lange","year":"2016","unstructured":"Lange AE, Thyrian JR, Wetzka S, Flessa S, Hoffmann W, Zygmunt M, et al. The impact of socioeconomic factors on the efficiency of voluntary toxoplasmosis screening during pregnancy: a population-based study. BMC Pregnancy Childbirth. 2016;16:197. https:\/\/doi.org\/10.1186\/s12884-016-0966-0.","journal-title":"BMC Pregnancy Childbirth"},{"key":"859_CR161","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2024.1307427","author":"MW Lwin","year":"2024","unstructured":"Lwin MW, Cheng CY, Calderazzo S, Schramm C, Schlander M. Would initiating colorectal cancer screening from age of 45 be cost-effective in Germany? An individual-level simulation analysis. Front Public Health. 2024. https:\/\/doi.org\/10.3389\/fpubh.2024.1307427.","journal-title":"Front PUBLIC HEALTH"},{"key":"859_CR162","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00008469-199612002-00008","volume":"5","author":"B Manus","year":"1996","unstructured":"Manus B, Bragelmann R, Armbrecht U, Stolte M, Stockbrugger RW. Screening for gastrointestinal neoplasia: efficacy and cost of two different approaches in a clinical rehabilitation centre. Eur J Cancer Prev. 1996;5:49\u201355.","journal-title":"Eur J Cancer Prev"},{"key":"859_CR163","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1007\/s00384-005-0058-5","volume":"21","author":"M Menges","year":"2006","unstructured":"Menges M, Gartner B, Georg T, Fischinger J, Zeitz M. Cost-benefit analysis of screening colonoscopy in 40- to 50-year-old first-degree relatives of patients with colorectal cancer. Int J Colorectal Dis. 2006;21:596\u2013601. https:\/\/doi.org\/10.1007\/s00384-005-0058-5.","journal-title":"Int J Colorectal Dis"},{"key":"859_CR164","doi-asserted-by":"publisher","first-page":"e0270490","DOI":"10.1371\/journal.pone.0270490","volume":"17","author":"JC Mewes","year":"2022","unstructured":"Mewes JC, Lindenberg M, Vrijhoef H. Cost-effectiveness analysis of implementing screening on preterm pre-eclampsia at first trimester of pregnancy in Germany and Switzerland. PLoS ONE. 2022;17:e0270490. https:\/\/doi.org\/10.1371\/journal.pone.0270490.","journal-title":"PLoS ONE"},{"key":"859_CR165","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/bf03256127","volume":"6","author":"D Mueller","year":"2008","unstructured":"Mueller D, Gandjour A. Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women. Appl Health Econ Health Policy. 2008;6:113 EP-135. https:\/\/doi.org\/10.1007\/bf03256127.","journal-title":"Appl Health Econ Health Policy"},{"key":"859_CR166","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1111\/j.1524-4733.2009.00577.x","volume":"12","author":"D Mueller","year":"2009","unstructured":"Mueller D, Gandjour A. Cost-effectiveness of using clinical risk factors with and without DXA for osteoporosis screening in postmenopausal women. Value health: J Int Soc Pharmacoeconomics Outcomes Res. 2009;12:1106\u201317. https:\/\/doi.org\/10.1111\/j.1524-4733.2009.00577.x.","journal-title":"Value health: J Int Soc Pharmacoeconomics Outcomes Res"},{"issue":"9","key":"859_CR167","first-page":"807","volume":"44","author":"E M\u00fcller","year":"1999","unstructured":"M\u00fcller E, Berger K, Dennemark N, Oleen-Burkey M. Cost of bacterial vaginosis in pregnancy. Decision analysis and cost evaluation of a clinical study in Germany. J Reprod Med. 1999;44(9):807\u201314.","journal-title":"J Reprod Med"},{"key":"859_CR168","doi-asserted-by":"publisher","first-page":"EP191","DOI":"10.1016\/j.jhin.2016.02.013","volume":"93","author":"NT Mutters","year":"2016","unstructured":"Mutters NT, Gunther F, Frank U, Mischnik A. Costs and possible benefits of a two-tier infection control management strategy consisting of active screening for multidrug-resistant organisms and tailored control measures. J Hosp Infect. 2016;93:EP191\u2013196. https:\/\/doi.org\/10.1016\/j.jhin.2016.02.013.","journal-title":"J Hosp Infect"},{"key":"859_CR169","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1080\/03007995.2019.1654689","volume":"35","author":"S Neusser","year":"2019","unstructured":"Neusser S, Lux B, Barth C, Pahmeier K, Rhiem K, Schmutzler R, et al. The budgetary impact of genetic testing for hereditary breast cancer for the statutory health insurance. Curr Med Res Opin. 2019;35:2103\u201310. https:\/\/doi.org\/10.1080\/03007995.2019.1654689.","journal-title":"Curr Med Res Opin"},{"key":"859_CR170","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejogrb.2017.03.029","volume":"212","author":"KU Petry","year":"2017","unstructured":"Petry KU, Barth C, Wasem J, Neumann A. A model to evaluate the costs and clinical effectiveness of human papilloma virus screening compared with annual papanicolaoucytology in Germany. Eur J Obstet Gynecol Reprod Biol. 2017;212:132\u20139. https:\/\/doi.org\/10.1016\/j.ejogrb.2017.03.029.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"859_CR171","doi-asserted-by":"publisher","unstructured":"Rasch A, Perleth M. A short-term diagnostic and economic impact model of neonatal screening for cystic fibrosis. Modellierung der kurzfristigen diagnostischen und \u00f6konomischen Auswirkungen eines Neugeborenen-screenings auf Mukoviszidose. 2011;223:96103. https:\/\/doi.org\/10.1055\/s-0031-1271667.","DOI":"10.1055\/s-0031-1271667"},{"key":"859_CR172","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2217\/cer.15.42","volume":"4","author":"G Ruile","year":"2015","unstructured":"Ruile G, Djanatliev A, Kriza C, Meier F, Leb I, Kalender WA, et al. Screening for breast cancer with Breast-CT in a ProHTA simulation. J Comp effective ness Res. 2015;4:553\u201367. https:\/\/doi.org\/10.2217\/cer.15.42.","journal-title":"J Comp effective ness Res"},{"key":"859_CR173","doi-asserted-by":"publisher","unstructured":"Schaufler TM. Cost-effectiveness of preventing type-2-diabetes mellitus in Germany. Gesundheits\u00f6konomie und Qualit\u00e4tsmanagement. 2009;14:71 EP\u2009\u2013\u200975. https:\/\/doi.org\/10.1055\/s-2008-1027778","DOI":"10.1055\/s-2008-1027778"},{"key":"859_CR174","doi-asserted-by":"publisher","first-page":"EP191","DOI":"10.2165\/11532880-000000000-00000","volume":"8","author":"TM Schaufler","year":"2010","unstructured":"Schaufler TM, Wolff W. Cost effectiveness of preventive screening programmes for type 2 diabetes mellitus in germany. Appl Health Econ Health Policy. 2010;8:EP191\u2013202. https:\/\/doi.org\/10.2165\/11532880-000000000-00000.","journal-title":"Appl Health Econ Health Policy"},{"key":"859_CR175","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1055\/s-0031-1275840","volume":"136","author":"M Schneider","year":"2011","unstructured":"Schneider M, Hack H-J. Screening for colorectal cancer: A cost benefit analysis on a health prevention programme at the Boehringer Ingelheim Company. Dtsch Med Wochenschr. 2011;136:1047. https:\/\/doi.org\/10.1055\/s-0031-1275840. EP\u2009\u2013\u20091052.","journal-title":"Dtsch Med Wochenschr"},{"key":"859_CR176","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1007\/s10096-009-0778-5","volume":"28","author":"M Schulz","year":"2009","unstructured":"Schulz M, Nonnenmacher C, Mutters R. Cost-effectiveness of rapid MRSA screening in surgical patients. Eur J Clin Microbiol Infect diseases: official publication Eur Soc Clin Microbiol. 2009;28:1291\u20136. https:\/\/doi.org\/10.1007\/s10096-009-0778-5.","journal-title":"Eur J Clin Microbiol Infect diseases: official publication Eur Soc Clin Microbiol"},{"key":"859_CR177","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/gim.2014.190","volume":"17","author":"F Severin","year":"2015","unstructured":"Severin F, Stollenwerk B, Holinski-Feder E, Meyer E, Heinemann V, Giessen-Jung C, Rogowski W. Economic evaluation of genetic screening for Lynch syndrome in Germany. Genet medicine: official J Am Coll Med Genet. 2015;17:765\u201373. https:\/\/doi.org\/10.1038\/gim.2014.190.","journal-title":"Genet medicine: official J Am Coll Med Genet"},{"key":"859_CR178","doi-asserted-by":"publisher","first-page":"EP279","DOI":"10.1097\/00008469-199808000-00003","volume":"7","author":"A Sieg","year":"1998","unstructured":"Sieg A, Hertel A, John MR, Luthgens K, Schmidt-Gayk H. Screening for colorectal neoplasms with a new immunological human faecal haemoglobin and albumin test. Eur J Cancer Prev. 1998;7:EP279\u2013285. https:\/\/doi.org\/10.1097\/00008469-199808000-00003.","journal-title":"Eur J Cancer Prev"},{"key":"859_CR179","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1055\/s-2007-963435","volume":"45","author":"A Sieg","year":"2007","unstructured":"Sieg A, Brenner H. Cost-saving analysis of screening colonoscopy in Germany. Z Gastroenterol. 2007;45:945\u201351. https:\/\/doi.org\/10.1055\/s-2007-963435.","journal-title":"Z Gastroenterol"},{"key":"859_CR180","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1016\/j.ejca.2011.03.006","volume":"47","author":"G Sroczynski","year":"2011","unstructured":"Sroczynski G, Schnell-Inderst P, M\u00fchlberger N, Lang K, Aidelsburger P, Wasem J, et al. Cost-effectiveness of primary HPV screening for cervical cancer in Germany\u2014a decision analysis. Eur J Cancer. 2011;47:1633\u201346. https:\/\/doi.org\/10.1016\/j.ejca.2011.03.006.","journal-title":"Eur J Cancer"},{"key":"859_CR181","first-page":"317","volume":"91","author":"T Szucs","year":"1996","unstructured":"Szucs T, Osterkorn D, Schramm W. [Public health economic evaluation of screening for APC resistance (Leiden mutation) in new oral contraceptive users]. Gesundheits\u00f6konomische Evaluation des Screenings auf APC-Resistenz (Mutation Leiden) bei Neuanwenderinnen von Ovulationshemmern. 1996;91:317\u20139.","journal-title":"Gesundheits\u00f6konomische Evaluation des Screenings auf APC-Resistenz (Mutation Leiden) bei Neuanwenderinnen von Ovulationshemmern"},{"key":"859_CR182","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12916-017-0924-3","volume":"15","author":"M Treskova","year":"2017","unstructured":"Treskova M, Aumann I, Golpon H, Vogel-Claussen J, Welte T, Kuhlmann A. Trade-off between benefits, harms and economic efficiency of low-dose CT lung cancer screening: a microsimulation analysis of nodule management strategies in a population-based setting. BMC Med. 2017;15:162. https:\/\/doi.org\/10.1186\/s12916-017-0924-3.","journal-title":"BMC Med"},{"key":"859_CR183","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10198-009-0156-3","volume":"11","author":"DK Tscheulin","year":"2010","unstructured":"Tscheulin DK, Drevs F. The relevance of unrelated costs internal and external to the healthcare sector to the outcome of a cost-comparison analysis of secondary prevention: the case of general colorectal cancer screening in the German population. Eur J health economic: HEPAC: health Econ Prev care. 2010;11:141\u201350. https:\/\/doi.org\/10.1007\/s10198-009-0156-3.","journal-title":"Eur J health economic: HEPAC: health Econ Prev care"},{"key":"859_CR184","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1136\/jech.51.2.180","volume":"51","author":"PG Warmerdam","year":"1997","unstructured":"Warmerdam PG, de Koning HJ, Boer R, Beemsterboer PM, Dierks ML, Swart E, Robra BP. Quantitative estimates of the impact of sensitivity and specificity in mammographic screening in Germany. J Epidemiol Commun Health. 1997;51:180\u20136. https:\/\/doi.org\/10.1136\/jech.51.2.180.","journal-title":"J Epidemiol Commun Health"},{"key":"859_CR185","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1055\/s-2004817998","volume":"129","author":"S Webendorfer","year":"2004","unstructured":"Webendorfer S, Messerer P, Eberle F, Zober A. [Precautions for intestinal cancer in the workplace. An initiative for secondary prevention in the BASF joint-stock company]. Dtsch Med Wochenschr. 2004;129:239\u201343. https:\/\/doi.org\/10.1055\/s-2004817998.","journal-title":"Dtsch Med Wochenschr"},{"key":"859_CR186","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s15010-012-0373-z","volume":"41","author":"P Weber","year":"2013","unstructured":"Weber P, Eberle J, Bogner JR, Schrimpf F, Jansson V, Huber-Wagner S. Is there a benefit to a routine preoperative screening of infectivity for HIV, hepatitis B and C virus before elective orthopaedic operations? Infection. 2013;41:479\u201383. https:\/\/doi.org\/10.1007\/s15010-012-0373-z.","journal-title":"Infection"},{"key":"859_CR187","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/2047-783x-15-4-145","volume":"15","author":"E Wolf","year":"2010","unstructured":"Wolf E, Blankenburg M, Bogner JR, Becker W, Gorriahn D, Mueller MC, et al. Cost impact of prospective HLA-B*5701-screening prior to abacavir\/lamivudine fixed dose combination use in Germany. Eur J Med Res. 2010;15:145\u201351. https:\/\/doi.org\/10.1186\/2047-783x-15-4-145.","journal-title":"Eur J Med Res"},{"key":"859_CR188","doi-asserted-by":"publisher","unstructured":"Friedrichs M, Friedel H, Bodeker W. Participant structure and economic benefit of prevention bonus programmes in company health insurance funds. Kosteneffektivit\u00e4t der orthoptischen Reihenuntersuchung im Kindergarten zur Fr\u00fcherkennung visueller Entwicklungsst\u00f6rungen. 2009;71:EP623\u2013627. https:\/\/doi.org\/10.1055\/s-0029-1239571.","DOI":"10.1055\/s-0029-1239571"},{"key":"859_CR189","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.healthpol.2009.12.015","volume":"96","author":"S Stock","year":"2010","unstructured":"Stock S, Schmidt H, Buscher G, Gerber A, Drabik A, Graf C, et al. Financial incentives in the German Statutory Health Insurance: new findings, new questions. Health Policy. 2010;96:51\u20136. https:\/\/doi.org\/10.1016\/j.healthpol.2009.12.015.","journal-title":"Health Policy"},{"key":"859_CR190","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s00038-008-7026-0","volume":"53","author":"S Stock","year":"2008","unstructured":"Stock S, Stollenwerk B, Klever-Deichert G, Redaelli M, Buscher G, Graf C, et al. Preliminary analysis of short-term financial implications of a prevention bonus program: first results from the German Statutory Health Insurance. Int J PUBLIC HEALTH. 2008;53:78\u201386. https:\/\/doi.org\/10.1007\/s00038-008-7026-0.","journal-title":"Int J PUBLIC HEALTH"},{"key":"859_CR191","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13034-023-00693-w","volume":"17","author":"T Waldmann","year":"2023","unstructured":"Waldmann T, Schaible J, Stiawa M, Becker T, Wegscheider K, Adema B, et al. The cost-utility of an intervention for children and adolescents with a parent having a mental illness in the framework of the German health and social care system: a health economic evaluation of a randomized controlled trial. Child Adolesc Psychiatry Mental Health. 2023;17:141. https:\/\/doi.org\/10.1186\/s13034-023-00693-w.","journal-title":"Child Adolesc Psychiatry Mental Health"},{"key":"859_CR192","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/hec.584","volume":"10","author":"A Briggs","year":"2001","unstructured":"Briggs A, O\u2019Brien B. The Death of Cost-minimisation Analysis? Health Econ. 2001;10:179\u201384. https:\/\/doi.org\/10.1002\/hec.584.","journal-title":"Health Econ"},{"key":"859_CR193","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2023.10.024","author":"F Catal\u00e1-L\u00f3pez","year":"2024","unstructured":"Catal\u00e1-L\u00f3pez F, Ridao M, Tejedor-Romero L, Caulley L, Hutton B, Husereau D, et al. Transparency, openness, and reproducible research practices are frequently underused in health economic evaluations. J Clin Epidemiol. 2024. https:\/\/doi.org\/10.1016\/j.jclinepi.2023.10.024.","journal-title":"J Clin Epidemiol"},{"key":"859_CR194","unstructured":"National Institute for Health and Care Excellence. The guidelines manual. NICE process and methods. PMG6. 2012. Available from: www.nice.org.uk\/process\/pmg6. Accessed 30 Jun 2025."},{"key":"859_CR195","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2471\/BLT.15.164418","volume":"94","author":"MY Bertram","year":"2016","unstructured":"Bertram MY, Lauer JA, de Joncheere K, Edejer T, Hutubessy R, Kieny M-P, Hill SR. Cost-effectiveness thresholds: pros and cons. Bull World Health Organ. 2016;94:925\u201330. https:\/\/doi.org\/10.2471\/BLT.15.164418.","journal-title":"Bull World Health Organ"},{"key":"859_CR196","unstructured":"World Health Organization. Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. 2001. http:\/\/apps.who.int\/iris\/bitstream\/10665\/42435\/1\/924154550X.pdf. Accessed 30 Jun 2025."},{"key":"859_CR197","doi-asserted-by":"publisher","first-page":"176","DOI":"10.12688\/gatesopenres.13201.1","volume":"4","author":"YL Chi","year":"2020","unstructured":"Chi YL, Blecher M, Chalkidou K, Culyer A, Claxton K, Edoka I, et al. What next after GDP-based cost-effectiveness thresholds? Gates Open Res. 2020;4:176. https:\/\/doi.org\/10.12688\/gatesopenres.13201.1.","journal-title":"Gates Open Res"},{"key":"859_CR198","doi-asserted-by":"publisher","first-page":"118","DOI":"10.2471\/blt.14.138206","volume":"93","author":"E Marseille","year":"2015","unstructured":"Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015;93:118\u201324. https:\/\/doi.org\/10.2471\/blt.14.138206.","journal-title":"Bull World Health Organ"},{"key":"859_CR199","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/1364557032000119616","volume":"8","author":"H Arksey","year":"2005","unstructured":"Arksey H, O\u2019Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8:19\u201332. https:\/\/doi.org\/10.1080\/1364557032000119616.","journal-title":"Int J Soc Res Methodol"},{"key":"859_CR200","unstructured":"World Health Organization. Mental health. 2022. https:\/\/www.who.int\/news-room\/fact sheets\/detail\/mental-health-strengthening-our-response. Accessed 30 Jun 2025."},{"key":"859_CR201","unstructured":"World Health Organization. Occupational Health. 2025. Available from: https:\/\/www.who.int\/healthtopics\/occupational-health. Accessed 30 Jun 2025."},{"key":"859_CR202","unstructured":"Sagan A, McDaid D, Rajan S, Farrington J. McKee Mn. Screening: When is it appropriate and how can we get it right? European Observatory on Health Systems and Policies. Copenhagen; 2020."},{"key":"859_CR203","unstructured":"WHO Framework Convention on Tobacco Control, World Health Organization, editor, WHO Framework Convention on Tobacco Control. 2003. Available from: https:\/\/wkc.who.int\/resources\/publications\/i\/item\/9241591013. Accessed 30 Jun 2025."},{"key":"859_CR204","unstructured":"European Centre for Disease Prevention and Control. European Vaccination Information Portal. 2025. Available from: https:\/\/vaccination-info.europa.eu\/en\/about-vaccines. Accessed 30 Jun 2025."}],"container-title":["Health Economics Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13561-026-00859-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13561-026-00859-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13561-026-00859-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:03:29Z","timestamp":1790384609000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13561-026-00859-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":204,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["859"],"URL":"https:\/\/doi.org\/10.1186\/s13561-026-00859-0","relation":{},"ISSN":["2191-1991"],"issn-type":[{"value":"2191-1991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"assertion":[{"value":"16 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"109"}}